KYV101-007

Treatment tested

• KYV-101
• Standard lymphodepletion regimen

Compared with

• Anti-CD20 mAB
• Ublituximab

  B-lymphocyte antigen CD20 binding agent

• Ocrelizumab

  B-lymphocyte antigen CD20 binding agent

• Ofatumumab

  B-lymphocyte antigen CD20 binding agent

• Rituximab

  B-lymphocyte antigen CD20 binding agent

Other measures (14)

Key Inclusion Criteria: 1. Subject must have a history of diagnosis of primary progressive or secondary progressive MS. 2. History of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months, with documented clinical disability progression within the 2 years prior to inclusion. Key Exclusion Criteria: 1. Monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, progressive solitary sclerosis or relapsing-remitting disease as defined by the 2017 McDonald criteria. 2. History of CNS or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, sarcoidosis, non-MS progressive neurologic condition or PML. 3. Prior treatment with cellular therapy (CAR-T) or gene therapy product directed at any target 4. History of allogeneic or autologous stem cell transplant 5. Evidence of active hepatitis B or hepatitis C infection 6. Positive serology for HIV 7. Primary immunodeficiency 8. History of splenectomy 9. History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject 10. Impaired cardiac function or clinically significant cardiac disease 11. Previous or concurrent malignancy with the following exceptions: 1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening) 2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening 3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis